Andrew Dean Clinical Oncology Society of Australia Annual Scientific Meeting 2020

Abstracts this author is presenting:

• NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. — Posters
• First-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase 1/2 study — Posters